DESTINY-Breast09 & the Future of Care – Dr. Irene Kang & Dr. Aditya Bardia

Recorded live, this in-depth conversation features Dr. Irene Kang and Dr. Aditya Bardia breaking down the DESTINY-Breast09 data and what it means for first-line treatment of metastatic HER2-positive breast cancer.

From challenging the long-standing THP standard to unpacking unprecedented progression-free survival, higher complete response rates, and CNS activity with T-DXd, this discussion explores how and why first-line decision-making is evolving. The panel also dives into patient selection, toxicity management, ILD monitoring, dose optimization, induction vs maintenance strategies, and how to frame these advances in real-world patient conversations.

A must-watch for clinicians navigating the next era of HER2-positive metastatic breast cancer care.